Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock

Abstract

Mantle cell lymphoma is an aggressive subtype of B cell non-Hodgkin lymphoma. It can progress to leukemic phase but frank leukemic picture at initial presentation is not common. Leukemic phase indicates advance stage of the disease and generally associated with extensive extra-nodal involvement. Pericardial invasion has been reported, however we could not find a report of myocardial infiltration by this disease since the appraisal of the term “mantle cell lymphoma” in 1992. Here we report a case of cardiac involvement by mantle cell leukemia leading to cardiogenic shock which complicates the treatment decisions.

Keywords

mantle cell lymphoma / bendamustine / cardiogenic shock

References

[1] BanksPM, ChanJ, ClearyML, DelsolG, Wolf-PeetersCD, GatterK, GroganTM, HarrisNL, IsaacsonPG, JaffeES, MasonD, PileriS, RalfikiaerE, SteinH, WarnkeRA. Mantle cell lymphoma.A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol1992; 16(7): 637-640

[2] ShivdasaniRA, HessJL, SkarinAT, PinkusGS. Intermediate lymphocytic lymphoma: clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma. J Clin Oncol1993; 11(4): 802-1118478674

[3] CampoE, RaffeldM, JaffeES. Mantle-cell lymphoma. Semin Hematol1999; 36(2): 115-127

[4] ArmitageJ. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma.The Non-Hodgkin’s Lymphoma Classification Project. Blood1997; 89(11): 3909-3918

[5] PittalugaS, BijnensL, TeodorovicI, HagenbeekA, MeerwaldtJH, SomersR, ThomasJ, NoordijkEM, De Wolf-PeetersC. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation. Blood1996; 87(10): 4358-4367

[6] KauhJ, BaidasSM, OzdemirliM, ChesonBD. Mantle cell lymphoma: clinicopathologic features and treatments. Oncology (Williston Park, NY)2003; 17(6): 879-891, 896; discussion 896-878

[7] BigoniR, NegriniM, VeroneseML, CuneoA, CastoldiGL, CroceCM. Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene1996; 13(4): 797-802

[8] ArgatoffLH, ConnorsJM, KlasaRJ, HorsmanDE, GascoyneRD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood1997; 89(6): 2067-2078

[9] SamahaH, DumontetC, KettererN, MoulletI, ThieblemontC, BouafiaF, Callet-BauchuE, FelmanP, BergerF, SallesG, CoiffierB. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia1998; 12(8): 1281-1287

[10] Parry-JonesN, MatutesE, MorillaR, Brito-BabapulleV, WotherspoonA, SwansburyGJ, CatovskyD. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH. Br J Haematol2007; 137(2): 117-124

[11] FerryJA. Extranodal lymphoma. Arch Pathol Lab Med2008; 132(4): 565-578

[12] AmbinderAJ, ShenoyPJ, NastoupilLJ, FlowersCR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer2013; 119(8): 1570-1577

[13] BertiniM, RusC, FreiloneR, BottoB, CalviR, NoveroD, OrsucciL, VitoloU, PalestroG, ResegottiL. Mantle cell lymphoma: a retrospective study on 27 patients.Clinical features and natural history. Haematologica1998; 83(4): 312-316

[14] BernardM, GressinR, LefrèreF, DrénouB, BrangerB, Caulet-MaugendreS, TassP, BrousseN, ValensiF, MilpiedN, VoilatL, SadounA, GhandourC, HunaultM, LeloupR, MannoneL, HermineO, LamyT. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia2001; 15(11): 1785-1791

[15] FerrerA, BoschF, VillamorN, RozmanM, GrausF, GutiérrezG, MercadalS, CampoE, RozmanC, López-GuillermoA, MontserratE. Central nervous system involvement in mantle cell lymphoma. Ann Oncol2008; 19(1): 135-141

[16] EveHE, FurtadoMV, HamonMD, RuleSA. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol2009; 27(32): e189-e190, author reply e191

[17] MartinP, ChadburnA, ChristosP, WeilK, FurmanRR, RuanJ, ElstromR, NiesvizkyR, ElyS, DilibertoM, MelnickA, KnowlesDM, Chen-KiangS, ColemanM, LeonardJP. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol2009; 27(8): 1209-1213

[18] GhielminiM, RufibachK, SallesG, Leoncini-FransciniL, Léger-FalandryC, CogliattiS, FeyM, MartinelliG, StahelR, LohriA, KettererN, WernliM, CernyT, SchmitzSF. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol2005; 16(10): 1675-1682

[19] GhielminiM, SchmitzSFH, CogliattiS, BertoniF, WaltzerU, FeyMF, BetticherDC, ScheferH, PichertG, StahelR, KettererN, BargetziM, CernyT; Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol2005; 23(4): 705-711

[20] SchulzH, BohliusJF, TrelleS, SkoetzN, ReiserM, KoberT, SchwarzerG, HeroldM, DreylingM, HallekM, EngertA. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst2007; 99(9): 706-714

[21] CangS, MukhiN, WangK, LiuD. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol2012; 5(1): 64

[22] WangK, WeiG, LiuD. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol2012; 1(1): 36

[23] CoiffierB. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin’s lymphoma. Semin Oncol2002; 29(2 Suppl 6): 18-22

[24] ZhaoJ, XuZ, LiuD, LuQ. Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting. Cancer Cell Int2012; 12(1): 38

[25] GhielminiM, ZuccaE. How I treat mantle cell lymphoma. Blood2009; 114(8): 1469-1476

[26] RummelMJ, NiederleN, MaschmeyerG, BanatGA, von GrünhagenU, LosemC, Kofahl-KrauseD, HeilG, WelslauM, BalserC, KaiserU, WeidmannE, DürkH, BalloH, StauchM, RollerF, BarthJ, HoelzerD, HinkeA, BruggerW; Study group indolent Lymphomas (StiL).Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet2013; 381(9873): 1203-1210

[27] JacobsonCA, FreedmanAS. First-line treatment of indolent lymphoma: axing CHOP? Lancet2013; 381(9873): 1163-1165

[28] LuK, WangX. Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol2012; 5(1): 55

[29] AkinleyeA, FurqanM, MukhiN, RavellaP, LiuD. MEK and the inhibitors: from bench to bedside. J Hematol Oncol2013; 6:27

[30] WuM, AkinleyeA, ZhuX. Novel agents for chronic lymphocytic leukemia. J Hematol Oncol2013;6:36

[31] ZhaoY, HuangH, WeiG. Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol2013;6:40

[32] WangML, RuleS, MartinP, GoyA, AuerR, KahlBS, JurczakW, AdvaniRH, RomagueraJE, WilliamsME, BarrientosJC, ChmielowskaE, RadfordJ, StilgenbauerS, DreylingM, JedrzejczakWW, JohnsonP, SpurgeonSE, LiL, ZhangL, NewberryK, OuZ, ChengN, FangB, McGreivyJ, ClowF, BuggyJJ, ChangBY, BeaupreDM, KunkelLA, BlumKA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med2013; 369(6): 507-516

[33] ByrdJC, FurmanRR, CoutreSE, FlinnIW, BurgerJA, BlumKA, GrantB, SharmanJP, ColemanM, WierdaWG, JonesJA, ZhaoW, HeeremaNA, JohnsonAJ, SukbuntherngJ, ChangBY, ClowF, HedrickE, BuggyJJ, JamesDF, O’BrienS. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med2013; 369(1): 32-42

[34] AkinleyeA, ChenY, MukhiN, SongY, LiuD. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol2013; 6:59

Acknowledgements

Yamei Chen is supported by a grant from Xiamen Zhongshan Hospital, Fujian, China and by NYMC Blood Disease Fund.

Compliance with the ethics guideline

Muhammad Furqan, Yamei Chen, Akintunde Akinleye, Judy Sarungbam, Alan Gass, Karen Seiter, and Delong Liu declare that they have no conflict of interest. Informed consent from the patient was obtained for this report.

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg